Strategic Board Appointments CGT Global has been expanding its strategic leadership with new Board of Advisors focused on cell and gene therapy policy and market access, signaling potential for partnerships in policy navigation, regulatory support, and reimbursement strategy which could open access to funded programs and expanded market reach.

Partnership Growth A recent collaboration with Orgenesis to expand patient access and cell and gene therapy development across the United States indicates an openness to strategic alliances that can broaden service offerings, geographic reach, and joint go-to-market opportunities.

Expanded Advisory Expertise Appointments of MD/PhD experts in hematologic malignancies, immunology, and cellular therapies to the advisory board suggest credibility and a potential pathway to co-develop specialized services, premium CRO engagements, and access to high-value research programs.

Financial Scale Revenue in the mid-range of small to mid-market biotech CROs (25-50 million) combined with a 51-200 employee base positions CGT Global as a scalable partner for mid-stage cell and gene therapy trials, with opportunities for expanded project scopes and longer-term contracts.

Capabilities Suite CGT Global offers end-to-end capabilities from primary cell manufacturing to collection, processing, GMP leukopaks, PBMCs, and donor recruitment, paired with full lab services and scalable custom projects, which presents cross-sell opportunities to existing clients and entry points for adjacent CRO services.